Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males
- PMID: 8360844
- DOI: 10.1002/jps.2600820707
Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males
Abstract
Nicardipine hydrochloride, a dihydropyridine calcium channel blocker, possesses antihypertensive and arterial vasodilator properties. A system analysis approach, which makes fewer structural assumptions than compartmental methods, is presented for determining the pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males following a discontinuous infusion at four dose levels. The results indicate that the average total body clearance of nicardipine is 0.920 L/h/kg and the volume of distribution is 0.275 L/kg. Nicardipine hydrochloride has a mean residence time in the body of 1.27 h, of which 0.324 h were spent in the systemic circulation and the remainder in the periphery. The determined pharmacokinetic model was linked to a pharmacodynamic model that allowed the change in the mean arterial blood pressure and heart rate to be described and predicted. A population pharmacokinetic-pharmacodynamic model was derived and the predictive power of the proposed model was assessed with a cross-validation technique that employs a relative predictive quotient for comparing the predictions to the fitted model. The results indicate that the proposed model describes the pharmacodynamics of nicardipine in healthy males and has good predictive ability when tested with a cross-validation procedure.
Similar articles
-
Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function.Anesth Analg. 1999 Nov;89(5):1116-23. Anesth Analg. 1999. PMID: 10553821 Clinical Trial.
-
A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.J Pharmacokinet Biopharm. 1993 Oct;21(5):489-514. doi: 10.1007/BF01059111. J Pharmacokinet Biopharm. 1993. PMID: 8145128
-
Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.Br J Clin Pharmacol. 1991 Jul;32(1):57-62. doi: 10.1111/j.1365-2125.1991.tb05613.x. Br J Clin Pharmacol. 1991. PMID: 1888642 Free PMC article.
-
Clevidipine: a review of its use in the management of acute hypertension.Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Am J Cardiovasc Drugs. 2009. PMID: 19331440 Review.
-
Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine.Am Heart J. 1990 Feb;119(2 Pt 2):427-34. doi: 10.1016/s0002-8703(05)80063-8. Am Heart J. 1990. PMID: 1967896 Review.
Cited by
-
A PBPK modeling approach for personalized dose optimization of nicardipine in renal and hepatic dysfunction.Sci Rep. 2025 Jun 5;15(1):19752. doi: 10.1038/s41598-025-03829-4. Sci Rep. 2025. PMID: 40473654 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources